Drug profile · INN
eladocagene exuparvovec
UPSTAZA
eladocagene exuparvovec (UPSTAZA) is a ddc exogenous gene.
EMA: approved Alimentary tract and metabolism (A16) A16AB26
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — eladocagene exuparvovec
- Class
- Alimentary tract and metabolism (A16)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
eladocagene exuparvovec (UPSTAZA) is a ddc exogenous gene.
Key facts
INN eladocagene exuparvovec
Brand UPSTAZA
Mechanism DDC exogenous gene
Target DDC
Therapeutic class Alimentary tract and metabolism (A16)
ATC code A16AB26
Mechanism of action
DDC exogenous gene
Primary target: DDC
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is eladocagene exuparvovec?
eladocagene exuparvovec (UPSTAZA) is a ddc exogenous gene.
What is the brand name for eladocagene exuparvovec?
UPSTAZA is a marketed brand name for eladocagene exuparvovec. Check FDA Drugs@FDA for the current US label holder and prescribing information.